Kurs & Likviditet
+52,15%
|
83,8 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2024-11-06 | Kvartalsrapport 2024-Q3 |
2024-08-22 | Kvartalsrapport 2024-Q2 |
2024-06-06 | Ordinarie utdelning AZT 0.00 NOK |
2024-06-05 | Årsstämma 2024 |
2024-05-08 | Kvartalsrapport 2024-Q1 |
2024-02-01 | Bokslutskommuniké 2023 |
2023-11-02 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-06-07 | Ordinarie utdelning AZT 0.00 NOK |
2023-06-06 | Årsstämma 2023 |
2023-05-04 | Kvartalsrapport 2023-Q1 |
2023-02-02 | Bokslutskommuniké 2022 |
2022-10-27 | Kvartalsrapport 2022-Q3 |
2022-08-18 | Kvartalsrapport 2022-Q2 |
2022-06-23 | Årsstämma 2022 |
2022-05-27 | Ordinarie utdelning AZT 0.00 NOK |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-01-27 | Bokslutskommuniké 2021 |
2021-10-28 | Kvartalsrapport 2021-Q3 |
2021-08-19 | Kvartalsrapport 2021-Q2 |
2021-05-21 | Ordinarie utdelning AZT 0.00 NOK |
2021-05-20 | Årsstämma 2021 |
2021-04-22 | Kvartalsrapport 2021-Q1 |
2021-01-28 | Bokslutskommuniké 2020 |
2020-10-22 | Kvartalsrapport 2020-Q3 |
2020-08-19 | Kvartalsrapport 2020-Q2 |
2020-05-15 | Ordinarie utdelning AZT 0.00 NOK |
2020-05-14 | Årsstämma 2020 |
2020-04-23 | Kvartalsrapport 2020-Q1 |
2020-01-30 | Bokslutskommuniké 2019 |
2020-01-06 | Extra Bolagsstämma 2020 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-16 | Ordinarie utdelning AZT 0.00 NOK |
2019-05-15 | Årsstämma 2019 |
2019-04-30 | Kvartalsrapport 2019-Q1 |
2019-01-30 | Bokslutskommuniké 2018 |
2018-10-18 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-09 | Ordinarie utdelning AZT 0.00 NOK |
2018-05-07 | Årsstämma 2018 |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-02-01 | Bokslutskommuniké 2017 |
2017-10-19 | Kvartalsrapport 2017-Q3 |
2017-08-17 | Kvartalsrapport 2017-Q2 |
2017-05-12 | Ordinarie utdelning AZT 0.00 NOK |
2017-05-11 | Årsstämma 2017 |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-02 | Bokslutskommuniké 2016 |
2016-10-26 | Kvartalsrapport 2016-Q3 |
2016-08-17 | Kvartalsrapport 2016-Q2 |
2016-05-12 | Ordinarie utdelning AZT 0.00 NOK |
2016-05-11 | Årsstämma 2016 |
2016-04-19 | Kvartalsrapport 2016-Q1 |
2016-02-11 | Bokslutskommuniké 2015 |
2016-02-11 | Kapitalmarknadsdag 2016 |
2015-11-03 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-05-13 | Ordinarie utdelning AZT 0.00 NOK |
2015-05-12 | Årsstämma 2015 |
2015-05-05 | Kvartalsrapport 2015-Q1 |
2015-02-17 | Bokslutskommuniké 2014 |
2014-11-05 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Kvartalsrapport 2014-Q2 |
2014-05-15 | Ordinarie utdelning AZT 0.00 NOK |
2014-05-14 | Årsstämma 2014 |
2014-04-30 | Kvartalsrapport 2014-Q1 |
2014-02-14 | Bokslutskommuniké 2013 |
2013-11-01 | Kvartalsrapport 2013-Q3 |
2013-08-09 | Kvartalsrapport 2013-Q2 |
2013-06-13 | Kapitalmarknadsdag 2013 |
2013-05-28 | Ordinarie utdelning |
2013-05-27 | Årsstämma 2013 |
2013-05-07 | Kvartalsrapport 2013-Q1 |
2013-02-01 | Extra Bolagsstämma 2013 |
2013-01-07 | Bokslutskommuniké 2012 |
2012-11-06 | Kvartalsrapport 2012-Q3 |
2012-08-10 | Kvartalsrapport 2012-Q2 |
2012-05-07 | Ordinarie utdelning AZT 0.00 NOK |
2012-05-07 | Årsstämma 2012 |
2012-05-07 | Kvartalsrapport 2012-Q1 |
2012-02-21 | Bokslutskommuniké 2011 |
2011-11-08 | Kvartalsrapport 2011-Q3 |
2011-08-10 | Kvartalsrapport 2011-Q2 |
2011-05-13 | Kvartalsrapport 2011-Q1 |
2011-05-13 | Årsstämma 2011 |
2011-05-12 | Ordinarie utdelning |
2011-02-17 | Bokslutskommuniké 2010 |
2010-11-12 | Kvartalsrapport 2010-Q3 |
2010-08-10 | Kvartalsrapport 2010-Q2 |
2010-05-11 | Kvartalsrapport 2010-Q1 |
2010-05-04 | Årsstämma 2010 |
2010-03-03 | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2020-04-22 17:33:31
(Tromsø 22. April 2020) Biotec Pharmacon ASA (OSE: "BIOTEC") announced today that its Board of Directors has unanimously appointed Dr Jethro Holter as the Company's permanent Chief Executive Officer. Dr Holter has been the interim CEO for the last 6 months Jethro joined ArcticZymes as Managing Director in January 2015. He focused on driving a new strategic direction channelling the subsidiary's efforts towards growth, through expanding its B2B client base and implementing a customer-driven innovation approach for new product development. Consequently, the subsidiary has experienced strong revenue growth and vastly expanded its portfolio of novel enzyme products. Today, ArcticZymes is profitable and a leading commercial supplier of enzymes to the molecular biology, In Vitro Diagnostics (IVD) and gene therapy market segments. During his time as interim CEO, Jethro has implemented a new Group strategy and continued to drive healthy growth in the business. "The Board of Directors is pleased to announce Jethro Holter as the CEO for Biotec Pharmacon ASA going forward. After being hired as the interim CEO 6 months ago, the Board is confident he has the necessary skills and background required to drive the company into profitability and long-term value creation.", says Chairman of the Board Dr Marie Roskrow "I am delighted in being appointed CEO. It is an exciting time to lead this company which is in a transition phase with a fresh and inspiring strategic direction. With the talented team behind me, I am confident we can aspire to maximise growth and transform the company into becoming Europe's leading one -stop-shop for enzymes. As the newly appointed CEO, my first priority will be to drive the company into profitability.", says CEO Jethro Holter The Company will present its Q1 2020 results tomorrow morning at 0830 For further information, please contact: Jethro HolterHethro Marie Roskrow CEO Chairman of the Board +47 46 85 91 46 Mobile: +44 (0) 7496 959743 Jethro.holter@biotec.no